[Memorandum from Daniel R. Lucey]

3. Mr Smith told Dr Vahey that she must understand that LCOL Redfield is
under alot of pressure from the NIH and the scientific community (e.g. Dr
Fauci was specifically mentioned) with regard to the gpl60 study. Mr
Smith asked Dr Vahey if she is aware that the Army's HIV clinical trials
are the best designed studies, and that some of the NIH's are poorly
designed.
4. Mr Smith told Dr Vahey that she must understand that there are also
financial pressures from the pharaceutical companies to consider. The
outcome of LCOL Redfield's gpl60 study could influence the willingness
and interest of other companies to work with LCOL Redfield, and other
persons associated with this gpl 60 study, in the future.
5. Mr Smith also told Dr Vahey that she must understand that there are
Congressional pressures on LCOL Redfield which must be considered with
regard to his HIV vaccine trials.
6. Mr Smith also told Dr Vahey that she should present the HIV viral
burden data on the same 15 patients that LCOL Redfield presented in
Amsterdam, as well as the subgroup of the 7 patients that LCOL Redfield
originally submitted on the abstract for the HIV vaccine meeting. Mr
Smith also said Dr Vahey should look at the data by subgroups such as the
patients in the Phase I study who were "early responders" compared with
those who were "late responders".
7. Mr Smith said he wants Dr Vahey to get the data documenting the
date of seroconversion for each of the patients. Mr Smith said this after
Dr Vahey mentioned that patient #1 in the Phase I study had only been
infected a relatively short time when he first started on the gpl160
injections and that this fact could possibly play a role in his clinical and
laboratory evaluations.
Dr Vahey referred to patient # 1 after Mr Smith asked her about patient
# 1, as the patient that DrNelson Michael ad Dr Vahey had evaluated so
extensively. Mr Smith asked Dr Vahey if she thought patient # 1 was an
anomaly, compared with the other patients. Dr Vahey replied that
patient # 1 was different than most of the other patients. At this point,
Dr Vahey also mentioned that this patient was HIV-seropositive for a
relatively short time before starting on the gpl60.